Gossamer Bio Inc. (NASDAQ:GOSS) saw an upside of 6.52% to close Monday at $13.39 after adding $0.82 on the day. The 5-day average trading volume is 492,020 shares of the company’s common stock. It has gained $13.58 in the past week. An average of 673,800 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 562,234.
GOSS’s 1-month performance is 33.23% or $3.34 on its low of $9.92 reached on 09/13/21. The company’s shares have touched a 52-week low of $7.04 and high of $14.10, with the stock’s rally to the 52-week high happening on 09/27/21. YTD, GOSS has achieved 38.47% or $3.72. However, the current price is down -5.04%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Mar 23, 203 days have gone by since the last insider trading activity for Gossamer Bio Inc. (GOSS). Giraudo Bryan (Chief Financial Officer) most recently sold 5,490 shares at $9.48 per share on Mar 23. This transaction cost the insider $52,046. Chief Scientific Officer, Salter-Cid Luisa, sold 5,491 shares at a price of $9.48 on Mar 23.
Gossamer Bio Inc. (GOSS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.GOSS stock has a beta of 0.00. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 4.52.
Gossamer Bio Inc.’s quick ratio for the period ended June 29 was 13.90, with the current ratio over the same period at 13.90 meaning that GOSS stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.80, while the total debt to equity was 0.80. The firm’s gross profit as reported stood at $12.67 million against revenue of $233.96 million.
For the quarterly period ending June 29 this year, Gossamer Bio Inc.’s cash and short-term investments amounted to $63.47 million against total debt of $185.24 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected GOSS to announce -$0.76 per share in earnings in its latest quarter, but it posted -$0.8, representing a -5.30% surprise. EBITDA for the quarter stood at more than -$52.57 million. GOSS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 211.82 million, with total debt at $185.24 million. Shareholders hold equity totaling $75.99 million
Let’s look briefly at Gossamer Bio Inc. (GOSS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 69.78% to suggest the stock is trending Neutral, with historical volatility in this time period at 53.68%.
The stock’s 5-day moving average is $12.57, reflecting a +7.03% or $0.88 change from its current price. GOSS is currently trading +28.63% above its 20-day SMA, +47.30% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +70.36% and +29.62% respectively.
Stochastic %K and %D was 63.00% and 57.77% and the average true range (ATR) pointed at 0.73. The RSI (14) points at 68.75%, while the 14-day stochastic is at 76.64% with the period’s ATR at 0.69. The stock’s 9-day MACD Oscillator is pointing at 0.08 and 0.15 on the 14-day charts.